Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and South-East Asia nations. HCC related to the pathogenesis of hepatitis B, hepatitis C, both alcoholic and non-alcoholic steatohepatitis (continuing to increase due to the rise of obesity and diabetes rate). Although, there are lot of progresses, however, tumor recurrence, distant metastasis and chemotherapy resistance remain mainly barrier in treatment of HCC. The advances in gene mutation research, molecular targeted therapy is developing as a new hope for better disease control. Histologic classification of tumors according to World Heath Organization has been widely applied and practiced worldwide. The fifth modified and supplemented classification for primary tumors in liver was given histological subtypes of HCC that related to molecular characteristics. Further understanding on subtypes of HCC such as macrotrabecular massive HCC, fibrolamellar HCC, lympho rich HCC... accompaning with molecular changes of the primary liver tumor will bring value for prognosis and contribute to better HCC management